Search Results 71-80 of 17302 for egfr

  1. A Study Using Avelumab in Non-Small Cell Lung Cancer that has Progressed - Mayo Clinic

    ... EGFR-targeting tyrosine kinase inhibitor (TKI) given before or after ... Subjects whose disease harbors an activating EGFR mutation who received an EGFR ...

  2. Non-Small Cell Lung Cancer Clinical Trials - Mayo Clinic Research

    Additional patients limited to those with EGFR mutations may be enrolled following the initial study period as needed to ensure adequate sample sizes needed to ...

  3. CAR-T Cell Therapy Clinical Trials - Mayo Clinic Research

    ... EGFR And Have Lost HLA-A*02 Expression Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN. The goal of this study is to test A2B395, an allogeneic logic ...

  4. Stem Cell Therapy for Chronic Kidney Disease - Mayo Clinic

    Estimated glomerular filtration rate (eGFR) 25-55 ml/min/1.73m^2. Spot urine albumin:creatinine ≥ 30 mg/g unless on RAAS inhibition. Ability to give ...

  5. Study Of Efficacy And Safety Of LNP023 In Primary IgA Nephropathy Patients - Mayo Clinic

    * Male and female patients ≥ 18 years of age with an eGFR level and biopsy-confirmed IgA nephropathy as follows: * For patients eGFR\* ≥ 45ml/min/1.73m2 ...

  6. A Study to Evaluate Bardoxolone Methyl in Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) - Mayo Clinic

    - Screening eGFR (average of Screen A and Screen B eGFR values) ≥ 30 to≤ 90 mL/min/1.73 m2 (18 to 55 years) or ≥ 30 to ≤ 44 mL/min/1.73 m2 (56 to 70 ...

  7. A Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD Patients - Mayo Clinic

    ... (eGFR) decline in patients at risk of ... *Eligibility will be confirmed by eGFR value from one of the two first pre-randomization eGFR measurements.

  8. Ravulizumab in Immunoglobulin A Nephropathy (IgAN) - Mayo Clinic

    The primary objective of this study to evaluate the efficacy of ravulizumab compared with placebo to reduce proteinuria and slow the rate of eGFR decline in ...

  9. A Clinical Study To Test If An Investigational Treatment Called BNT326 Is Safe And Potentially Beneficial When Used Alone Or In Combination With Other Investigational Treatments Such As BNT327, For People With Advanced Malignant Tumors - Mayo Clinic

    ... EGFR Tyrosine Kinase Inhibitors (TKI), with at least one being a third-generation EGFR TKI. If there is no third-generation EGFR TKI approved as part of SoC ...

  10. Erlotinib (oral route) - Side effects & dosage - Mayo Clinic

    ... (EGFR) gene mutations. Your doctor will perform a test before you take this medicine. This medicine is also used together with another medicine called ...